Myasnikov Alexander G, Kundhavai Natchiar S, Nebout Marielle, Hazemann Isabelle, Imbert Véronique, Khatter Heena, Peyron Jean-François, Klaholz Bruno P
Centre for Integrative Biology (CBI), Department of Integrated Structural Biology, IGBMC (Institute of Genetics and of Molecular and Cellular Biology), 1 rue Laurent Fries, Illkirch 67404, France.
Centre National de la Recherche Scientifique (CNRS) UMR 7104, Illkirch, France.
Nat Commun. 2016 Sep 26;7:12856. doi: 10.1038/ncomms12856.
Many antibiotics in clinical use target the bacterial ribosome by interfering with the protein synthesis machinery. However, targeting the human ribosome in the case of protein synthesis deregulations such as in highly proliferating cancer cells has not been investigated at the molecular level up to now. Here we report the structure of the human 80S ribosome with a eukaryote-specific antibiotic and show its anti-proliferative effect on several cancer cell lines. The structure provides insights into the detailed interactions in a ligand-binding pocket of the human ribosome that are required for structure-assisted drug design. Furthermore, anti-proliferative dose response in leukaemic cells and interference with synthesis of c-myc and mcl-1 short-lived protein markers reveals specificity of a series of eukaryote-specific antibiotics towards cytosolic rather than mitochondrial ribosomes, uncovering the human ribosome as a promising cancer target.
许多临床使用的抗生素通过干扰蛋白质合成机制来靶向细菌核糖体。然而,迄今为止,在诸如高度增殖的癌细胞等蛋白质合成失调的情况下靶向人类核糖体尚未在分子水平上进行研究。在此,我们报告了带有一种真核生物特异性抗生素的人类80S核糖体的结构,并展示了其对几种癌细胞系的抗增殖作用。该结构为人类核糖体配体结合口袋中的详细相互作用提供了见解,这些相互作用是结构辅助药物设计所必需的。此外,白血病细胞中的抗增殖剂量反应以及对c-myc和mcl-1短寿命蛋白质标志物合成的干扰揭示了一系列真核生物特异性抗生素对胞质核糖体而非线粒体核糖体的特异性,表明人类核糖体是一个有前景的癌症靶点。